Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

NCT07357051 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Viral Infection

Interventions

DRUG: JKN2301 Dry Suspension
DRUG: Oseltamivir Placebo
DRUG: Oseltamivir
DRUG: JKN2301 Placebo

Sponsor

Joincare Pharmaceutical Group Industry Co., Ltd